PRINCETON, N.J.--(BUSINESS WIRE)--The Geistlich Surgery, USA business unit of Geistlich Pharma AG, a family owned, Swiss-based global leader in regenerative solutions, is proud to announce the launch of its latest advancement: Geistlich Nexo-Gide® Dual Surface Membrane. Geistlich Pharma has received 510(k) clearance from the United States Food and Drug Administration to market Geistlich Nexo-Gide® for the management and protection of tendon injuries in which there has been no substantial loss of tendon tissue.
“Tendon injuries remain a persistent clinical challenge,” said Carrie Hartill, Business Unit Director for Geistlich Surgery. “With an increase in sports participation combined with an aging population, tendon and ligament injuries account for nearly half of the 32 million musculoskeletal injuries each year. Clinicians are looking to increase the likelihood of a positive surgical outcome and need a versatile, flexible option with distinct features to meet this need for patients who require surgical treatment. To be used as a clinical solution for patients who suffer from tendon injuries that require surgical intervention, this new offering will further our commitment to deliver high quality regenerative medicine solutions with the goal of giving patients a better quality of life.”
Geistlich Nexo-Gide® will be featured at this year’s Podiatry Institute: Hallux Valgus & Related Foot Surgery meeting that will take place in Fort Myers, Florida, on November 4-7 as well as the Orthopaedic Summit in Las Vegas, Nevada on December 11-14.
About Geistlich Nexo-Gide
Geistlich Nexo-Gide® Dual Surface Membrane is a resorbable, highly purified, naturally dual surface bilayer (and therefore structurally optimal) collagen membrane for the management and protection of tendon injuries. The porcine-derived (Collagen I/III) membrane serves as a biocompatible protective encasement to support the body’s healing process. The product is manufactured using a unique, patented process.
For more information on Geistlich Surgery, USA, visit www.nexogide.com.
Geistlich Nexo-Gide® is a registered trademark of Geistlich Pharma, AG
About Geistlich Pharma
Geistlich Surgery, USA is a business unit of Geistlich Pharma AG, which is headquartered in Switzerland. Entirely family owned since 1851, the company develops, produces, and markets medical devices for regenerative medicine and pharmaceuticals. More than 700 employees worldwide work for Geistlich in the area of regenerative medicine. With its twelve affiliates and 60 distribution partners, Geistlich’s medical devices and medicinal products reach around 90 markets worldwide.
